Natalie Keshing Editor-in-Chief Nats.news This Article was posted February 3, 2020
“Based on recently published scientific papers, this new coronavirus has unprecedented virologic features that suggest genetic engineering may have been involved in its creation.“
The sudden outbreak of the Wuhan Novel Coronavirus (COVID-19) has resulted in all of China’s Hubei Province and three major cities in Zhejiang Province being subjected to quarantine. Other nations were anxiously trying to get their people out of China. Restrictions were being placed on flights to China. The novel coronavirus virus was proving to have an extremely high transmission speed and a high fatality rate, it had already started to pose as a significant challenge to public health, not only in China, but around the world.
There were major gaps in knowledge of the virus’s origin, duration of human-to-human transmission, and clinical management of those infected based on the current limited information coming from China. Nevertheless, the findings of those scientists who have recently published research papers about this virus are summarized below.
Lancet Article Reports Wuhan Virus Was Not Likely Caused by Natural Recombination
Most papers reported that the COVID-19 is only 88 percent related to the closest bat coronavirus, only 79 percent to SARS, and just 50 percent to MERS. Professor Roujian Lu from the China Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, and his co-authors commented in a Jan. 30 paper in Lancet that “recombination is probably not the reason for emergence of this virus.”
A January 27, 2020, a study by 5 Greek scientists analyzed the genetic relationships of COVID-19 and found that
1) “the new coronavirus provides a new lineage (lineal descent) for almost half of its genome (a full set of chromosomes), with no close genetic relationships to other viruses within the subgenus of sarbecovirus,”
2) “and has an unusual middle segment never seen before in any coronavirus”
3) all this indicates is that COVID-19 is a brand new type of coronavirus.
4) The study’s authors rejected the original hypothesis that COVID-19 originated from random natural mutations between different coronaviruses.
Paraskevis et al 2020 BioRxiv
The article is a preprint made available through bioRxiv and has not been peer-reviewed.
A Very High Genetic Identity in Patients Indicates a Recent Transmission to Human
1) COVID-19 is an RNA (ribonucleic acid: any of a class of single-stranded molecules transcribed from DNA in the cell nucleus) virus.
2) RNA viruses have high natural mutation rates. The Lancet study by Lu et al. states: “As a typical RNA virus, the average evolutionary rate for coronaviruses is roughly 104 nucleotide substitutions per site per year, with mutations arising during every replication cycle.
3) It is, therefore, striking that the sequences of COVID-19 from different patients described here were almost identical
4) With greater than 99.9% sequence identity. This finding suggests that COVID-19 originated from one source within a very short period and detected relatively rapidly.
A January 31, 2020 article by Jon Cohen in Science said:
1) “The longer a virus circulates in a human population, the more time it has to develop mutations that differentiate strains in infected people, and given that the COVID-19 sequences analyzed to date differ from each other by seven nucleotides at most, this suggests it jumped into humans very recently.”
But it remains a mystery which animal spread the virus to humans.
Bat or Huanan Market Source Is Not the Whole Story
Professor Lu et. al. discussed the natural host of the virus.
1) An early hypothesis had been the virus had passed to humans from bats sold at Wuhan’s Huanan Seafood Market.
Lu et. al write:
1) First, the outbreak was first reported in late December 2019, when most bat species in Wuhan are hibernating.
2) Second, no bats were sold or found at the Huanan seafood market, whereas various non-aquatic animals (including mammals) were available for purchase.
3) Third, the sequence identity between COVID-19 and its close relatives bat-SL-CoVZC45 and bat-SL-CoVZXC21 was less than 90%.
4) Hence, bat-SL-CoVZC45 and bat-SL-CoVZXC21 ARE NOT DIRECT ANCESTORS of COVID-19.
The authors point out that while the COVID-19 causing the Wuhan outbreak might have initially been hosted by bats, it may have been transmitted to humans via other as yet unknown mechanism.
The Science article said: “Huanan marketplace played an early role in spreading COVID-19, but whether it was the origin of the outbreak remains uncertain.
1) Many of the initially confirmed COVID-19 cases; 27 of the first 41 in one report, 26 of 47 in another were connected to the Wuhan market.
2) But up to 45%, including the earliest handful, were not.
3) This raises the possibility that the initial jump into people happened elsewhere.
Spike Protein Has 4 Precise Mutations Without Impacting Its Affinity for Human Receptor
Every virus must have a receptor to bind to human cells, can only live inside human cells, and must rely on human cells to replicate. Without these capabilities, viruses found circulating in blood or tissue fluids are easily cleared by the human immune system.
Viruses enter human cells via specific surface protein channels. The interaction of viral surface proteins binding to human cells is similar with how keys are used to open locks.
1) Previous studies have shown there are several receptors that different coronavirus bind to, such as angiotensin-converting enzyme 2 (ACE2) for SARS-CoV.
2) ACE2 receptors are abundantly present in human tissue, especially along the epithelial linings of lung and small intestines, provide routes of entry into cells for SARS-CoV.
According to Lu et al.’s Lancet paper, there is a structural similarity between the receptor-binding domains of SARS-CoV and COVID-19.
COVID-19 spike protein (S-protein) is responsible for binding to cell receptors and is crucial for viral targeting of host tissue.
The molecular modelling data by Lu et. al. suggests that, despite the presence of amino acid mutations in the COVID-19 receptor-binding domain, COVID-19 might use the ACE2 receptor to gain entry into host cells.
On January 21, 2020, Xintian Xu et al. from Key Laboratory of Molecular Virology and Immunology, Institute Pasteur of Shanghai, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Shanghai, China, published a paper entitled:
“Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission” in SCIENCE CHINA Life Sciences. This paper provided a more precise analysis of the S-protein of Wuhan COVID-19.
1) The S-protein was known to usually have the most variable amino acid sequences compared to other gene domains from coronavirus.
2) However, despite considerable genetics distance between the Wuhan COVID-19 and the human-infecting SARS-CoV, and the overall low homology (a structural similarity of two segments of one animal based on a common developmental origin) of the Wuhan COVID-19 S-protein to that of SARS-CoV, the Wuhan COVID-19 S-protein had several patches of sequences in the receptor binding (RBD) domain with a high homology to that of SARS-CoV.
The residues at positions 442, 472, 479, 487, and 491 in SARS-CoV S-protein were reported to be at receptor complex interface and considered critical for cross species and human-to-human transmission of SARS-CoV.
So to their surprise, despite replacing four out of five important interface amino acid residues, the Wuhan COVID-19 S-protein was found to have a significant binding affinity to human ACE2.
The replacing residues at positions 442, 472, 479, and 487 in the Wuhan COVID-19 S-protein did not alter the structural confirmation The Wuhan COVID-19 S-protein and SARS-CoV S-protein shared an almost identical 3-D structure in the RBD domain, thus maintaining similar van der Waals and electrostatic properties in the interaction interface. Thus the Wuhan COVID-19 is still able to pose a significant public health risk for human transmission via the S protein–ACE2 binding pathway.” (emphasis added)
We know already that the novel COVID-19 is a different virus than SARS. It is understood that S-protein is highly variable. It would be no surprise if the genetic sequence, protein structure, and even the function of COVID-19’s S-protein is different than that of the SARS virus. But, how could this novel virus be so intelligent as to mutate precisely at selected sites while preserving its binding affinity to the human ACE2 receptor? How did the virus change just four amino acids of the S-protein? Did the virus know how to use Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) to make sure this would happen?
Stunning Finding: S-Protein Insertions From HIV
On January 27, 2020, Prashant Pradhan et. al. from the Indian Institute of Technology published a paper entitled “Uncanny similarity of unique inserts in the COVID-19 spike protein to HIV-1 gp120 and Gag,” which is currently being revised. The corresponding author of this paper, Professor Bishwajit Kundu, is specialized in protein genetic and genetic engineering and has published about 41 papers during the past 17 years on PubMed, including high-impact biomedical journals.
The authors found 4 insertions in the spike glycoprotein (S) which are unique to the COVID-19 and are not present in other coronaviruses.
“Importantly, amino acid residues in all 4 inserts have identity or similarity to those of HIV-1 gp120 or HIV-1 Gag. Interestingly, despite the inserts being discontinuous on the primary amino acid sequence, 3D-modelling of the COVID-19 suggests that they converge to constitute the receptor binding site. The finding of 4 unique inserts in the COVID-19, all of which have identity/similarity to amino acid residues in key structural proteins of HIV-1 is unlikely to be fortuitous (happening or produced by chance; accidental) in nature.”
Pradhan et al. added, “To our surprise, these sequence insertions were not only absent in S-protein of SARS but were also not observed in any other member of the Coronaviridae family.”
“This is startling as it is quite unlikely for a virus to have acquired such unique insertions naturally in a short duration of time.”
“Unexpectedly, all the insertions got aligned with Human immunodeficiency Virus-1 (HIV-1). Further analysis revealed that aligned sequences of HIV-1 with COVID-19 were derived from surface glycoprotein gp120 (amino acid sequence positions: 404-409, 462-467, 136-150) and from Gag protein (366-384 amino acid).
Gag protein of HIV is involved in host membrane binding, packaging of the virus and for the formation of virus-like particles. Gp120 plays crucial role in recognizing the host cell by binding to the primary receptor CD4. This binding induces structural rearrangements in GP120, creating a high affinity binding site for a chemokine co-receptor like CXCR4 and/or CCR5.”
It is well known that CD4 cells are essential to human immunity and are the direct targets of the Human Immunodeficiency Virus or HIV. HIV attaches to CD4 cells, enters and infects them. The virus then turns each infected CD4 cell into a factory creating more HIV virus until eventually all CD4 cells are destroyed. People infected with HIV lose their immunity or defense system which is like a country losing the function of its army.
If we take a closer look at the 4 insertions of the S-protein, they are all located on the binding surface of the protein, seemly designed to be able to bind to target cell receptor sites. Natural accidental mutation would be randomly distributed across the whole length of the S-protein. It is highly unlikely that all of these insertions would coincidentally be manifested on the binding site of the S-protein.
The article by Pradhan et. al. is a preprint made available through bioRxiv and has not been peer-reviewed. bioRxiv reports:
Clinical Evidence: Patients Have Cytokine Storm with Progressive Decline in Blood Lymphocytes
Are Pradhan et. al.’s findings right or wrong? If correct, the virus should be able to invade human CD4 T cells and result in corresponding clinical features. A paper published in The Lancet on Jan. 24, 2020 by Professor Chaolin Huang from Jin Yin-tan Hospital, Wuhan, China, et. al., reviewing “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China” supports Pradhan et. al’s conclusions.
Huang analyzed 41 hospital patients admitted with laboratory-confirmed COVID-19 infection as of Jan. 2, 2020.
“Only 27 (66%) of 41 patients had been exposed to Huanan seafood market. Common symptoms at onset of illness were fever (98%), cough (76%), and myalgia or fatigue (44%); less common symptoms were sputum production (28%), headache (8%), haemoptysis (5%), and diarrhoea (3%). Dyspnoea developed in 55% (median time from illness onset to dyspnoea 8·0 days). 63% had lymphopenia.
All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (29%), RNAaemia (15%), acute cardiac injury (12%) and secondary infection (10%). 32% patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα. The COVID-19 infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality.”
Although low white blood cell counts are common in viral infections, it is surprising that 63 percent of all infected patients and 85 percent of those admitted to the ICU had lymphopenia with lymphocyte counts <1·0 × 109/L.
In a study on SARS published March 2004 by C.M. Chu et. al. in the journal Thorax, the mean lymphocyte count was often reported as normal.
On Jan. 22, 2020, two clinical guidelines for the diagnosis and treatment of Wuhan COVID-19 were posted on China websites.
One is “Quick Guide for the Diagnosis and Treatment of New Coronavirus Pneumonia” authored by the expert group of Tongji Hospital, and the other is “Instructions for Handling 2019 New Coronavirus” from the Wuhan Union Hospital of Tongji Medical College of Huazhong University of Science and Technology.
The first guideline clearly points out a “progressive lymphocyte reduction” while the second guideline highlights “the importance of monitoring the absolute value of lymphocytes.”
Therefore, the observed lymphocyte reduction must be of clinical significance in a certain proportion of patients. CD4 positive T lymphocytes constitute a major fraction of all lymphocytes. Although not a routine test for patients with coronavirus infection, perhaps monitoring CD4 cell counts would be helpful in COVID-19 patients.
Another clinical feature of patients infected with COVID-19 is the high levels of serum cytokines and chemokines, which is defined as a cytokine storm (Huang et al 2020 Lancet). This is consistent with the observation from Pradhan et al. that the COVID-19 S-protein inducing structural rearrangements in GP120, creating a high affinity binding site for a chemokine co-receptor such as CXCR4 and/or CCR5.
It is well known that activating T cell surface receptors can cause a cytokine storm. Cytokine storms have potential to create significant damage to organs and bodily tissues.
If a cytokine storm occurs in the lungs, for example, immune cells such as macrophages and fluid may trigger tissue damage that results in acute respiratory distress and possible death.
The United States Centers for Disease Control stated: “There is no specific antiviral treatment recommended for COVID-19 infection.” But, there are a few case reports of Wuhan COVID-19 patients benefiting from empiric treatment with anti-HIV drugs such as lopinavir. More such detailed clinical experience needs to be shared.
There are many scientific questions regarding this novel virus.
Based on recently published scientific papers, this new coronavirus has unprecedented virologic features that suggest genetic engineering may have been involved in its creation.
The virus presents with severe clinical features, which make it a significant threat. It is imperative for scientists, physicians, and people all over the world, including governments and public health authorities, to make every effort to investigate this mysterious and suspicious virus in order to elucidate its origin and to better enable populations in China and around the world to respond.
Yuhong Dong holds a M.D. from Beijing Medical University and a doctorate in infectious diseases from Beijing University. Dong has 17 years of working experience in viral infectious disease clinical treatment and antiviral drug research. Dong worked as a doctor in the First Affiliated Hospital of Beijing Medical University and then later as a Medical Scientific Expert specialized in antiviral drug clinical research in Novartis R&D. She currently works as a Chief Scientific Officer in a Swiss Biotech company.
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet 2020. Online Full Text
• Paraskevis D., Kostaki E.G., Magiorkinis G., et al. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. bioRxiv 2020.01.26.920249.Online Full Text
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 2020. Online Full Text
• Cohen Jon. Mining coronavirus genomes for clues to the outbreak’s origins. Science 2020.Online Full Text
• Pradhan P, Pandey AK, Mishra A, et al. Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag. bioRxiv 2020.01.30.927871. Online Full Text
• Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission, In Journal of SCIENCE CHINA Life Sciences. 2020 Online Full Text
• Chu CM, Cheng VC, Hung IF, et al. HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004 Mar;59(3):252-6.Online Full Text
• US CDC: Interim Clinical Guidance for Management of Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) Infectionhttps://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html
• Figure 2 source: https://phys.org/news/2018-10-farming-gene-editingan-oxymoron-tool.html